Erratum to: 'Effectiveness of biomarker-based exclusion of ventilator-acquired pneumonia to reduce antibiotic use (VAPrapid-2): study protocol for a randomised controlled trial'

Erratum to: ‘Effectiveness of biomarker-based exclusion of ventilator-acquired pneumonia to reduce antibiotic use (VAPrapid-2): study protocol for a randomised controlled trial’. Trials, 17(465), 1.

Published in: Trials

Document Version: Publisher's PDF, also known as Version of record

Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal

Publisher rights
Copyright 2018 the authors.
This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Erratum to: ‘Effectiveness of biomarker-based exclusion of ventilator-acquired pneumonia to reduce antibiotic use (VAPrapid-2): study protocol for a randomised controlled trial’

Thomas P. Hellyer¹, Niall H. Anderson², Jennie Parker³, Paul Dark⁴, Tina Van Den Broeck⁵, Suveer Singh⁶, Ronan McMullan⁷, Ashley M. Agus⁸, Lydia M. Emerson⁹, Bronagh Blackwood⁹, Savita Gossain¹⁰, Tim S. Walsh¹¹, Gavin D. Perkins¹², Andrew Conway Morris¹³, Daniel F. McAuley¹²,¹⁴ and A. John Simpson¹

Erratum
Unfortunately, the original version of this article [1] contained an error. There are two references in the text to the threshold for defining VAP as greater than \(10^4\) colony forming units/ml. These should read greater OR EQUIAL to \(10^4\) colony forming units/ml. The error is in the abstract and in the intervention sections.

In the abstract, please replace:

Patients with clinically suspected VAP undergo BAL and VAP is confirmed by growth of a potential pathogen at \(>10^4\) colony forming units per millilitre (CFU/ml).

With the following correct version:

Patients with clinically suspected VAP undergo BAL and VAP is confirmed by growth of a potential pathogen at \(\geq 10^4\) colony forming units per millilitre (CFU/ml).

In the Interventions, please replace:

VAP is confirmed by the widely used threshold of growth of a potential pathogen at \(>10^4\) colony forming units per ml (CFU/ml)(13).

With the following correct version:

VAP is confirmed by the widely used threshold of growth of a potential pathogen at \(\geq 10^4\) colony forming units per ml (CFU/ml)(13).

Author details
¹Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK. ²Centre for Population Health Sciences, University of Edinburgh, Medical School, Edinburgh, UK. ³Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK. ⁴Institute of Inflammation and Repair, University of Manchester, Manchester Academic Health Sciences Centre & Intensive Care Unit, Salford Royal NHS Foundation Trust, Greater Manchester, UK. ⁵Becton Dickinson Biosciences, Erembodegem, Aalst, Belgium. ⁶Intensive Care Unit, Chelsea and Westminster Hospital, Imperial College London, London, UK. ⁷Department of Medical Microbiology, Kelvin Building, The Royal Hospitals, Belfast, UK. ⁸Northern Ireland Clinical Trials Unit, Elliot Dyres Building, The Royal Hospitals, Belfast, UK. ⁹Centre for Experimental Medicine, Queen’s University Belfast, Belfast, UK. ¹⁰Public Health Laboratory, Heart of England NHS Foundation Trust, Birmingham, UK. ¹¹NRC Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK. ¹²University of Warwick and Heart of England NHS Foundation Trust, Coventry, UK. ¹³Division of Anaesthesia, Department of Medicine, University of Cambridge, Addenbrooke’s Hospital, Cambridge Biomedical Campus, Cambridge, UK. ¹⁴Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, UK.

Received: 30 August 2016 Accepted: 13 September 2016
Published online: 26 September 2016

Reference